ÂÜŔňÂŇÂ×

CM

Camilia R. Martin

Scientific Advisor at LUCA Biologics

Dr. Camilia R. Martin is a leading neonatologist and an Assistant Professor of Pediatrics at Harvard Medical School, the Associate Director of the Neonatal Intensive Care Unit and Director for Cross-Disciplinary Research Partnerships in the Division of Translational Research at Beth Israel Deaconess Medical Center (BIDMC). Dr. Martin has participated in multi-site clinical trials serving as the Principal Investigator at BIDMC resulting in publications evaluating growth and long-term neurodevelopmental outcomes in the extremely preterm infant.

Dr. Martin’s extensive body of research is focused on the health impacts of neonatal nutrition in preterm infants—specifically on development of immune defenses, postnatal intestinal and microbiome adaptation, fatty acid metabolism, regulation of the inflammatory response, and the nutritional impact on organogenesis. She has been cited over 3000 times and is an editor of Cloherty and Stark's Manual of Neonatal Care. Her work seeks to elucidate how we can optimize early-life nutrition, and the systems by which we provide this care, to cultivate healthy growth and development.

Dr. Martin received her M.D. from Cornell University School of Medicine and her master’s degree in epidemiology from the Harvard School of Public Health. She completed her internship and residency at Children’s Memorial Hospital/Northwestern School of Medicine, where she also served as chief pediatric resident. Her fellowship in perinatal-neonatal medicine was completed at the Harvard Combined Program in Neonatology. In 2009, Dr. Martin received a Harvard Catalyst Faculty Fellowship Award facilitating her transition from general epidemiology to translational research. In September 2014, Dr. Martin was awarded an R01 grant from NIDDK to examine the “Impact of fatty acid imbalance in intestinal health and disease in prematurity”. She currently serves as Senior Advisor and Co-Director of the Grant Review and Support Program (GRASP) through the Harvard Clinical and Translational Science Center (Harvard Catalyst).